Kiora Pharmaceuticals (KPRX) Prepaid Assets (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Prepaid Assets came in at $1.2 million in Q1 2026, up 28.12% YoY from $941542.0 in Q1 2025, and up 5.65% on a QoQ basis from $1.1 million in Q4 2025.
Kiora Pharmaceuticals (KPRX) Prepaid Assets (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 13 years of Prepaid Assets data on file, last reported at $1.2 million in Q1 2026.
- Quarterly Prepaid Assets rose 28.12% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (up 28.12% YoY) and the FY2025 annual result came in at $1.1 million, down 44.1% from the prior year.
- Prepaid Assets rose to $1.2 million in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $2.0 million in Q4 2024 to a low of $109439.0 in Q2 2022.
- A 5-year average of $629008.3 and a median of $470424.0 in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2022 — Prepaid Assets tumbled 75.17% — and 2024, when it jumped 775.17%.
- Tracing KPRX's Prepaid Assets over 5 years: stood at $343069.0 in 2022, then plunged by 31.97% to $233382.0 in 2023, then jumped by 775.17% to $2.0 million in 2024, then slumped by 44.1% to $1.1 million in 2025, then gained by 5.65% to $1.2 million in 2026.
- The last three Prepaid Assets figures came in at $1.2 million (Q1 2026), $1.1 million (Q4 2025), and $650429.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.13 Mn |
| Mar 31, 2026 | 1.21 Mn |
| Dec 31, 2025 | 1.14 Mn |
| Sep 30, 2025 | 650,429.00 |
| Jun 30, 2025 | 957,095.00 |
| Mar 31, 2025 | 941,542.00 |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 470,424.00 |
| Jun 30, 2024 | 339,646.00 |
| Mar 31, 2024 | 206,671.00 |
| Dec 31, 2023 | 233,382.00 |
| Sep 30, 2023 | 239,391.00 |
| Jun 30, 2023 | 266,500.00 |
| Mar 31, 2023 | 488,950.00 |
| Dec 31, 2022 | 343,069.00 |
| Sep 30, 2022 | 125,628.00 |
| Jun 30, 2022 | 109,439.00 |
| Mar 31, 2022 | 930,345.00 |
| Dec 31, 2021 | 606,520.00 |
| Sep 30, 2021 | 341,629.00 |